DANIEL ERNESTO
CASTELLANO GAUNA

2023

1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

   Prostate, Vol. 83, Núm. 4, pp. 376-384

2. Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

   Clinical Cancer Research, Vol. 29, Núm. 21

3. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

   Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53

4. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

   Annals of Oncology

5. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

   Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299

6. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib

   European urology, Vol. 83, Núm. 3, pp. 200-209

7. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

   Clinical and Translational Oncology

8. Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

   BMC Cancer, Vol. 23, Núm. 1

9. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

   Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687

10. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

11. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

12. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 9, pp. 391.e13-391.e21

13. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

14. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

    Cancer Medicine, Vol. 12, Núm. 11, pp. 12071-12083

15. Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features

    Frontiers in Oncology, Vol. 13

16. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

17. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience

    Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593

18. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

    Cancers, Vol. 15, Núm. 11

19. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    European Urology, Vol. 84, Núm. 3, pp. 321-330

20. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615